ArticleFrontiers in immunology2026

Efficacy and safety of zanubrutinib and camrelizumab combined with CD19 chimeric antigen receptor T-cell in the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Huan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.